CELC חוב כולל להון Celcuity Corp

Celcuity Inc. (CELC) is a promising player in targeted oncology diagnostics, utilizing the CELx system for personalized therapy selection. This price visualization, which assists in the basic asset assessment, demonstrates a debt-to-equity ratio of 0.00, complementing data on a stable staff of biologists with minimal turnover. Leveraging its scientific expertise, management aims to integrate its analytical solutions into the practice of major hospitals.

The financial leverage ratio determines a business's dependence on borrowed funds relative to its equity, signaling default risks or the cost of servicing obligations. By analyzing the total debt-to-equity ratio, an investor assesses the stability of Celcuity Inc. (CELC), whose development strategy in high-tech biotech requires significant expenditures for clinical trials and overcoming regulatory barriers.